Address: Bijster 14
4817 HX Breda
Nederland
Tel: +31 (0)85 111 96 00
Web: http://www.cslbehring.nl/home
CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture and market biotherapies that are used to treat serious and rare conditions. Users of our therapies rely on them for their quality of life and, in many cases, for life itself.
Our commitment to saving lives and improving the quality of life for people with serious and rare conditions is evident in everything we do. Whether we are manufacturing and marketing safe and effective products or researching and developing innovative biotherapies, we are first and foremost focused on fulfilling our customers’ needs.
CSL Behring is a specialty biotherapeutics company, serving people with rare and serious diseases around the globe for more than a century.
Biotherapies differ from conventional pharmaceuticals in that they treat diseases with products derived from human plasma or manufactured by recombinant technologies, while conventional pharmaceuticals derive their products from chemicals. Biotherapeutic proteins replace missing components in the blood.
CSL Behring develops, manufactures, and markets protein-based therapies in the Bleeding Disorders, Critical Care, Immunoglobulins, Pulmonary, and Wound Healing areas.
Paul Korte, General Manager for Janssen in the Netherlands, highlights the strategic move and leadership position taken up by Janssen in the oncology field, and calls on Dutch healthcare stakeholders…
In an exclusive interview, the Vice President of Philips Research explains the key to continuous evolution, improving healthcare stakeholder relations, and fostering “Open Innovation.” You have been Vice President of…
Healthcare is moving towards an increased level of personalization and active participation of the patient in the decision-making process. Roland van Esch, General Manager of Zimmer Biomet Netherlands, shares his…
Teva Benelux and Nordics’ GM lifts the lid on how the company has grown to become the market leader in the Netherlands. Looking at Teva’s activities, your market leader position in…
Takeda’s goal is to become a trusted and reliable partner in the healthcare system by better understanding patients’ needs. Aarnoud Overkamp, general manager of the Dutch subsidiary, shares his perspective…
In many aspects, 2016 truly marks the dawn of a new era for Toshiba Medical Systems. Lo Wuite (LW), General Manager Managed Equipment Services (MES) Europe, and Dick Blesing (DB),…
DHL Supply Chain Benelux understands the challenges life sciences companies face and has developed solutions to help overcome them. The Vice President and Commercial Director discuss how the services of…
Yvonne van Rooy, president of the NVZ, explains the patient’s increasing role as a partner in Dutch healthcare and how greater investment in ICT is needed for the patient to fulfill this role. She further discusses…
After having successfully acquired its first dialysis center in the Netherlands, Fresenius Medical Care, the market leader for kidney failure products and services, is looking to develop more partnerships with…
Ad Schuurman of the National Health Care Institute of the Netherlands (“Zorginstituut”) explains the main missions and mandates of this organization with regards to the basic insurance package covering all Dutch citizens,…
Kees Smaling, Managing Director of Siemens Healthcare, which recently completed its first Dutch (and European) hospital financing, explains the strategic thinking that sustains Siemens’ shift to become a more comprehensive…
DB Schenker’s Bart Coenen (BC) and Vincent Coolen (VC) explain the company’s Vision 2020 and talk about the benefits for pharma companies of outsourcing their supply chain. In 2013, DB…
See our Cookie Privacy Policy Here
